Frontiers in Cardiovascular Medicine

JANUARY 14, 2024

Introduction Statins remain the first-line treatment for secondary prevention of cardiovascular (CV) events, with lowering of low-density lipoprotein cholesterol (LDL-C) being their therapeutic target. Recurrent stroke occurs in up to 19% of patients seven years after a first cerebrovascular event.

Peripheral Arterial Disease 64

Peripheral Arterial Disease Cardiovascular Disease Cerebrovascular Disease Coronary Artery Disease 64

Frontiers in Cardiovascular Medicine

JANUARY 21, 2024

Background and aims Epidemiology of atherosclerotic cardiovascular disease might be different in patients with polygenic hypercholesterolemia plus high levels (≥30 mg/dl) of Lp(a) (H-Lpa) than in those with polygenic hypercholesterolemia alone (H-LDL). The median duration of follow-up was 10 years (IQR 3–16). 3.17, P  = 0.006).

Cardiovascular Disease 45

Cardiovascular Disease Peripheral Arterial Disease Cerebrovascular Disease Coronary Artery Disease 45

DAIC

JANUARY 23, 2024

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111